Focused On-demand Library for Nucleolar protein 56

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O00567

UPID:

NOP56_HUMAN

Alternative names:

Nucleolar protein 5A

Alternative UPACC:

O00567; Q2M3T6; Q9NQ05

Background:

Nucleolar protein 56, also known as Nucleolar protein 5A, plays a crucial role in the early to middle stages of 60S ribosomal subunit biogenesis. It is a core component of box C/D small nucleolar ribonucleoprotein (snoRNP) particles, essential for the biogenesis of box C/D snoRNAs such as U3, U8, and U14. This protein is part of the small subunit (SSU) processome, facilitating RNA folding, modifications, rearrangements, and cleavage, crucial for ribosome assembly.

Therapeutic significance:

Nucleolar protein 56 is implicated in Spinocerebellar ataxia 36, a disorder characterized by progressive incoordination and motor neuron system involvement. Understanding the role of Nucleolar protein 56 could open doors to potential therapeutic strategies for this debilitating condition.